Launxp Biomedical Co (ROCO:6876) ROCE %: -39.91% (As of Dec. 2025)


ROCO:6876 Launxp Biomedical Co Ltd ROCO:6876
11 GF Score
Price NT$15.90
! 4 Warning Signs
View Full Analysis

What is Launxp Biomedical Co ROCE %?

Launxp Biomedical Co ROCO:6876 -0.93% 11 ROCE % is -39.91% as of Dec. 2025. GuruFocus rates ROCO:6876 with a GF Score™ of 11/100. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Launxp Biomedical Co's annualized ROCE % for the quarter that ended in Dec. 2025 was -39.91%.

Launxp Biomedical Co  (ROCO:6876) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Launxp Biomedical Co ROCE % Related Terms

Launxp Biomedical Co ROCE % Historical Data

* Premium members only.

The historical data trend for Launxp Biomedical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Launxp Biomedical Co ROCE % Chart

Launxp Biomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -55.03 -92.80 -76.99 -55.63 -58.41

Launxp Biomedical Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -75.13 -45.29 -68.26 -52.28 -39.91
ROCO:6876
11GF Score
Launxp Biomedical Co Ltd ROCO:6876
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Launxp Biomedical Co ROCE % Calculation

Launxp Biomedical Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-109.414/( ( (123.911 - 13.934) + (403.034 - 138.339) )/ 2 )
=-109.414/( (109.977+264.695)/ 2 )
=-109.414/187.336
=-58.41 %

Launxp Biomedical Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-112.238/( ( (568.229 - 270.478) + (403.034 - 138.339) )/ 2 )
=-112.238/( ( 297.751 + 264.695 )/ 2 )
=-112.238/281.223
=-39.91 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -39.91% mean?
Launxp Biomedical Co (ROCO:6876) has a ROCE % of -39.91% as of Dec. 2025.
Is Launxp Biomedical Co's ROCE % too high?
Launxp Biomedical Co's current ROCE % is -39.91%. Overall, Launxp Biomedical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Launxp Biomedical Co's ROCE % compare to VRTX and REGN?
Launxp Biomedical Co's ROCE % of -39.91% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Launxp Biomedical Co's current ROCE % is -39.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Launxp Biomedical Co stock overvalued right now?
Launxp Biomedical Co (ROCO:6876) has a current ROCE % of -39.91%. The current ROCE % is -39.91%. Launxp Biomedical Co's overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Launxp Biomedical Co (ROCO:6876), the current ROCE % is -39.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Launxp Biomedical Co Business Description

Address 10F, No. 51, Section 2, Gongyi Road, Nantun District, Taichung, TWN, 408
Launxp Biomedical Co Ltd is a company that researches, designs and develops Cancer drug rapid screening platform and Early development evaluation and technology licensing of generic drugs for cancer treatment. The company mainly focuses on the screening of development drugs, formulation of development strategies, project management, planning and execution of regulations and clinical trials, etc.
11GF Score

Get the complete analysis for ROCO:6876

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$15.90
Price